長寿命の形質細胞がmRNAワクチン接種後に確立されず、接種したらその後感染しても未接種者ほどの長期的免疫効果が得られなくなると証明されてしまう。LoL

岩崎せんせは何故か触れられてませんが、
仮に長寿命の形質細胞が感染後の未接種者には確立してると証明されてしまったら…

…ってか未接種者が感染後の長期的免疫効果をゲットしてると証明してるデータが既にあったような…

2022年7月13日水曜日

新型コロナワクチン未接種者が自然感染回復し得た免疫の重症・死亡防止効果は、全ての変異種に対し１４か月以上低下せずに持続する９７．３％！

July 07, 2022. 　Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar

Abstract

BACKGROUND The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.

METHODS Three national, matched, retrospective cohort studies were conducted to compare incidence of SARS-CoV-2 infection and COVID-19 severity among unvaccinated persons with a documented SARS-CoV-2 primary infection, to incidence among those infection-naïve and unvaccinated. Associations were estimated using Cox proportional-hazard regression models.

RESULTS Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% (95% CI: 84.8-86.2%). Effectiveness peaked at 90.5% (95% CI: 88.4-92.3%) in the 7^th month after the primary infection, but waned to ∼70% by the 16^th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22^nd month and <10% by the 32^nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3-39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of <10% by the 15^th month. Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9- 98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age.

CONCLUSIONS Protection of natural infection against reinfection wanes and may diminish within a few years. Viral immune evasion accelerates this waning. Protection against severe reinfection remains very strong, with no evidence for waning, irrespective of variant, for over 14 months after primary infection.

https://www.medrxiv.org/content/10.1101/2022.07.06.22277306v1

未接種者が自然感染回復し得た免疫力の重症・死亡防止効果は、全ての変異種に対し１４か月以上低下せずに持続する９７．３％。

未接種者が自然感染回復し得た免疫力の重症・死亡防止効果は、全ての変異種に対し１４か月以上低下せずに持続する９７．３％。

未接種者が自然感染回復し得た免疫力の重症・死亡防止効果は、全ての変異種に対し１４か月以上低下せずに持続する９７．３％。

要するに・・・

未接種者は一回でも感染し回復するとその人にとって新型コロナは変異種を問わずせいぜい「ただの風邪」となるわけで・・・

https://tokumei10.blogspot.com/2022/07/blog-post_55.html

要するに、

mRNAワクチン接種者は未接種者と比較すると一回の感染で対新型コロナウイルス免疫弱者と化すわけです。

 おーい！まだ息してるかい？

対新型コロナ免疫弱者たるHNが長い人！

LoLLoLLoLLoLLoLLoLLoL
LoLLoLLoLLoLLoLLoLLoL
LoLLoLLoLLoL